Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
A longevity peptide with an unusually long human research history — almost entirely from a single research tradition that hasn't been independently replicated.
Epithalon has one of the more interesting evidence stories on this page: genuine decades-long human research — concentrated almost entirely in Russian literature, without independent Western replication. Both facts matter.
Epithalon (also spelled Epitalon) is a synthetic version of a compound derived from the pineal gland, developed primarily through Russian aging research. Its signature claim — that it activates telomerase, the enzyme that maintains the protective caps on chromosomes — comes from a body of research led largely by one research group over several decades.
A widely cited 2003 study reported that Epithalon activated telomerase and elongated telomeres in cultured human cells. Telomere shortening is genuinely associated with cellular aging, which is why a compound claimed to counteract it draws so much longevity interest.
This is a genuinely unusual case: more long-duration human observational data exists for Epithalon than for most peptides discussed here, but nearly all of it comes from one research tradition, published mostly in Russian-language journals, using methodology (often unblinded, observational) that wouldn't meet Western regulatory standards. Independent replication by Western research groups is essentially absent. More data does not automatically mean stronger evidence — the type and rigor of the studies matters as much as the quantity.
Reported issues in the available (mostly older, Russian) literature are minimal, but the absence of Western-standard controlled trials means a rigorous modern safety profile doesn't exist. As with the other investigational longevity compounds on this page, that's a reason for caution and supervision, not a green light.
Epithalon's research history is longer than most longevity peptides, but "long" and "rigorous by current standards" aren't the same thing. It's a legitimate area of scientific interest that hasn't yet been proven the way regulators or most Western clinicians would require — and that distinction should be part of any conversation about using it.
Regulatory status as of 2026-07-20.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense Epithalon or any medication.